[Federal Register Volume 70, Number 23 (Friday, February 4, 2005)]
[Notices]
[Page 6047]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 05-2138]


-----------------------------------------------------------------------

NUCLEAR REGULATORY COMMISSION

[Docket No. 030-20885]


Notice of Availability of Environmental Assessment and Finding of 
No Significant Impact for License Amendment for Genzyme Biosurgery's 
Facility in Ridgefield, NJ

AGENCY: Nuclear Regulatory Commission.

ACTION: Notice of availability.

-----------------------------------------------------------------------

FOR FURTHER INFORMATION CONTACT: Kathy Dolce Modes, Materials Security 
& Industrial Branch, Division of Nuclear Materials Safety, Region I, 
475 Allendale Road, King of Prussia, Pennsylvania 19406, telephone 
(610) 337-5251, fax (610) 337-5269; or by e-mail: <a href="/cdn-cgi/l/email-protection#83c8c2c7c3cdd1c0adc4ccd5"><span class="__cf_email__" data-cfemail="97dcd6d3d7d9c5d4b9d0d8c1">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION:

I. Introduction

    The Nuclear Regulatory Commission (NRC) is issuing a license 
amendment to Genzyme Biosurgery for Materials License No. 29-23308-01, 
to authorize release of its facility in Ridgefield, New Jersey for 
unrestricted use. NRC has prepared an Environmental Assessment (EA) in 
support of this action in accordance with the requirements of 10 CFR 
part 51. Based on the EA, the NRC has concluded that a Finding of No 
Significant Impact (FONSI) is appropriate. The amendment will be issued 
following the publication of this notice.

II. EA Summary

    The purpose of the action is to authorize the release of the 
licensee's Ridgefield, New Jersey facility for unrestricted use. 
Genzyme Biosurgery was authorized by NRC from December 23, 1983, to use 
radioactive materials for research and development purposes at the 
site. On June 4, 2004, Genzyme Biosurgery requested that NRC release 
the facility for unrestricted use. Genzyme Biosurgery has conducted 
surveys of the facility and provided information to the NRC to 
demonstrate that the site meets the license termination criteria in 
subpart E of 10 CFR part 20 for unrestricted use.
    The NRC staff has prepared an EA in support of the license 
amendment. The facility was remediated and surveyed prior to the 
licensee requesting the license amendment. The NRC staff has reviewed 
the information and final status survey submitted by Genzyme 
Biosurgery. Based on its review, the staff has determined that there 
are no additional remediation activities necessary to complete the 
proposed action. Therefore, the staff considered the impact of the 
residual radioactivity at the facility and concluded that since the 
residual radioactivity meets the requirements in subpart E of 10 CFR 
part 20, a Finding of No Significant Impact is appropriate.

III. Finding of No Significant Impact

    The staff has prepared the EA (summarized above) in support of the 
license amendment to terminate the license and release the facility for 
unrestricted use. The NRC staff has evaluated Genzyme Biosurgery's 
request and the results of the surveys and has concluded that the 
completed action complies with the criteria in subpart E of 10 CFR part 
20. The staff has found that the environmental impacts from the action 
are bounded by the impacts evaluated by NUREG-1496, Volumes 1-3, 
``Generic Environmental Impact Statement in Support of Rulemaking on 
Radiological Criteria for License Termination of NRC-Licensed 
Facilities'' (ML042310492, ML042320379, and ML042330385). On the basis 
of the EA, the NRC has concluded that the environmental impacts from 
the action are expected to be insignificant and has determined not to 
prepare an environmental impact statement for the action.

IV. Further Information

    Documents related to this action, including the application for the 
license amendment and supporting documentation, are available 
electronically at the NRC's Electronic Reading Room at http://www.nrc.gov/reading-rm/adams.html. From this site, you can access the 
NRC's Agencywide Document Access and Management System (ADAMS), which 
provides text and image files of NRC's public documents. The ADAMS 
accession numbers for the documents related to this notice are: 
Environmental Assessment (ADAMS Accession No. ML050270048), ``Report of 
the Decommissioning of the Genzyme Biosurgery Research and Development 
Laboratories for the Purpose of Surrendering the Company's Radioactive 
Materials License'' included with the licensee's letter dated June 4, 
2004 (ADAMS Accession No. ML041800154) and additional information dated 
October 15, 2004 (ADAMS Accession No. ML042990427). Please note that on 
October 25, 2004, the NRC terminated public access to ADAMS and 
initiated an additional security review of publicly available documents 
to ensure that potentially sensitive information is removed from the 
ADAMS database accessible through the NRC's Web site. Interested 
members of the public may obtain copies of the referenced documents for 
review and/or copying by contacting the Public Document Room pending 
resumption of public access to ADAMS. The NRC Public Documents Room is 
located at NRC Headquarters in Rockville, MD, and can be contacted at 
(800) 397-4209, (301) 415-4737 or by e-mail to <a href="/cdn-cgi/l/email-protection#fa8a9e88ba948899d49d958c"><span class="__cf_email__" data-cfemail="e7978395a7899584c9808891">[email protected]</span></a>.

    Dated in King of Prussia, Pennsylvania this 27th day of January, 
2005.

    For the Nuclear Regulatory Commission.
James P. Dwyer,
Chief, Commercial and R&D Branch, Division of Nuclear Materials Safety, 
Region I.
[FR Doc. 05-2138 Filed 2-3-05; 8:45 am]
BILLING CODE 7590-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>